TScan Therapeutics, Inc. (Nasdaq: TCRX) reported financial results for the third quarter ended September 30, 2026, and announced a strategic reorganization to prioritize its in vivo-engineered T cell receptor (TCR-T) cell therapy for solid tumors.
The company stated that it has paused further enrollment in the Phase 3 ALLOHA-2 study of its TSC-101 candidate to allow data to mature. The company is actively seeking strategic partners for its heme malignancies and autoimmunity programs.
In its solid tumor program, TScan is advancing two lead candidates through IND-enabling studies: one targeting PRAME and the other targeting MAGE-A4. The company anticipates filing the first IND for in vivo-engineered TCR-T for solid tumors in the third quarter of 2027, with the goal of dosing the first patient in the fourth quarter of 2027.
Financial results for the third quarter of 2026 included revenue of $0.6 million, compared to $2.5 million in the prior year period. Research and development expenses were $25.3 million, and general and administrative expenses were $8.3 million. The company reported a net loss of $33.1 million for the quarter.
As of September 30, 2026, TScan had cash and cash equivalents of $73.0 million, excluding $5.0 million of restricted cash. The company believes its existing cash resources will be sufficient to fund its current operating plan into the fourth quarter of 2027.
